Latest Drug Development News

Page 7 of 29
Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.
Ada Torres
Ada Torres
30 Apr 2026
Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.
Ada Torres
Ada Torres
29 Apr 2026
Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.
Ada Torres
Ada Torres
29 Apr 2026
IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.
Victor Sage
Victor Sage
28 Apr 2026
Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.
Ada Torres
Ada Torres
28 Apr 2026
Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.
Ada Torres
Ada Torres
28 Apr 2026
Noxopharm’s Sofra™ oligonucleotides, delivered via InhaTarget’s inhalable lipid nanoparticles, achieved a significant reduction in lung inflammation in preclinical models, broadening Sofra’s therapeutic reach and delivery versatility.
Ada Torres
Ada Torres
27 Apr 2026
Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.
Ada Torres
Ada Torres
24 Apr 2026
Noxopharm signed a strategic MoU with Tezcat Biosciences, published major Sofra RNA research, and appointed Dr Olivier Laczka as CEO, while reporting positive safety data from its HERACLES trial and improving cash flow.
Ada Torres
Ada Torres
24 Apr 2026
Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.
Ada Torres
Ada Torres
22 Apr 2026
Recce Pharmaceuticals has cleared a critical regulatory hurdle in Indonesia with a successful inspection of its Phase 3 clinical trial site for diabetic foot infections, paving the way for potential approval in 2026 amid a large and growing market.
Ada Torres
Ada Torres
21 Apr 2026
4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.
Ada Torres
Ada Torres
20 Apr 2026

Browse the archive

Full archive